Loading
Novacyt S.A. Stock: price and insider trades · United Kingdom
GB·Mcap £29M
No insider purchase over the last 90 days. The latest was filed 30 Mar 2026.
Novacyt S.A.: what insiders have been doing
Novacyt S.A. has a thin disclosure history in our data (latest filing: 30 March 2026). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€69,964
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySale1) CEO 2) Chairman 3) NED1 buy
Since the insiders bought
- +3.8%Entry £0.33 · Close at T+90 £0.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,381 of 24,148 companies
23.7
score / 100
Value4
Quality43
FCF yld-34%
Earn yld-79%
EV/EBITDA·
ROE-75%
Gross mgn63%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
£0.40
Analyst consensus
1 analysts£0.66Target £0.66(+65%)£0.66
Income statement
Revenue£20M
Gross profit£12.6M63% margin
EBITDA-£8.2M-41% margin
Net income-£22.9M-102.5% margin
Valuation
PER (forward)-574.3x
P/Book120.8x
Beta1.11
Balance sheet & cash
Market cap£29M
Total debt£10.5M
Free Cash Flow-£9.9M
Debt / Equity55%
Profitability & ownership
ROE-75.2%
ROA-12.9%
% insiders0.1%
% institutions0.0%
Last declaration on 30 March 2026
Declarations1 total
175,891 shares@ £0.3442100.0% of flow1 & 2) Euronext and 3) AIMRNS:b27f5f5d-5034-4b65-b25a-b14824d5c1bb
Canonical exit: 25 Jun 2026 (T+90)
1 of 1 declaration
About Novacyt S.A.
Novacyt S.A. is a biotechnology company focused on developing diagnostic tests for infectious diseases. It is listed on the London market under the ticker XLON.
